Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals LAUSANNE, Switzerland – December 20, 2019 – Nagi Bioscience SA, a Swiss life-science-tech company developing a revolutionary technology for the in vitro testing of drugs and chemicals, announced today the closingRead more about Nagi Bioscience is proud to announce the closing of a CHF 1.8M Seed financing round[…]
Read more Nagi Bioscience is proud to announce the closing of a CHF 1.8M Seed financing round
Bridging the gap...
On one side, unlike cell-based models, our solution allows assessing complete biological responses, only observable at a whole-organism level. On the other side, our technology allows getting these results at automation and throughput levels which are comparable to the cutting-edge of in vitro techniques.